Vanzacaftor
Vanzacaftor (VX-121) is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases[1][2].
Product Specifications
CAS Number
2374124-49-7
Product Name Alternative
VX-121
UNSPSC
12352005
Target
CFTR; Chloride Channel
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
COVID-19-immunoregulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/vanzacaftor.html
Purity
98.72
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC(C)(C[C@@](CCC/N=C1NC(S(=O)(N2)=O)=CC=C\1)([H])C3)N3C4=NC(N(C=C5)N=C5OCCC6C7(CC7)C68CC8)=CC=C4C2=O
Molecular Formula
C32H39N7O4S
Molecular Weight
617.76
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Naked1 (NKD1) Human qPCR Primer Pair (NM_033119)
Retinol Binding Protein-1 (G4E4), CF740 conjugate, 0.1mg/mL
L Kynurenine Hydrolase (KYNU) Rabbit Polyclonal Antibody
